The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
A Successful System of Scientific Data Audits for Clinical Trials: A Report From the Cancer and Leukemia Group B
Abstract
OBJECTIVE: To report on data collected during on-site audits of source documents in the Cancer and Leukemia Group B (CALGB). DESIGN: A retrospective review of audit reports in four audit cycles. SETTING: A cooperative group of institutions conducting clinical trials in cancer treatment. PARTICIPANTS: Patients taking part in clinical trials at collaborating CALGB institutions, members of the CALGB Data Audit Committee, and group chairmen of CALGB. MAIN OUTCOME MEASURE: The results of 691 institutional audits conducted by the CALGB in 1982 through 1992 with comparisons of main CALGB institutions vs affiliates. RESULTS: In four full reviews of all participating institutions in the CALGB, 3787 patients have had their on-site medical records compared with data submitted to the CALGB Data Management Center. Compliance with federal regulations for oversight by an institutional review board improved from a deficiency rate of 28.0% among the main institutions and 49.6% of the affiliate institutions in the first audit cycle to respective figures of 13.3% and 28.2% in the fourth cycle. Consent form deficiencies also dropped overall from 18.5% in the first cycle to 3.9% in the fourth. Patient eligibility was verified by auditors in 94.5%, and assessment of tumor changes in response to treatment was verified in 96.4% in the fourth cycle; both figures were only slightly lower in the first cycle. Two instances of scientific impropriety were discovered for a rate of only 0.28% of all audits. Both occurred prior to 1984, and none have occurred since. Major protocol deviations in drug dosing have held steady at about 11% over four audit cycles. Over the 11-year period of audits, three main institutions and 96 affiliate institutions have discontinued CALGB membership due solely, or at least partly, to unfavorable audit results. CONCLUSION: Scientific improprieties have occurred very rarely in clinical trials conducted by the CALGB. Protocol compliance in assessing patient eligibility and tumor responses has been high. Attention to administrative matters of consent forms, institutional review board approval, and ancillary data submission has measurably improved in the CALGB, which is at least partly due to the pressure from this on-site peer review of investigator performance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Random laboratory audits in cancer clinical trials, for example, found that only 0.28% contained ' scientific improprieties ' (4)”
From Is science really facing a reproducibility crisis, and do we need it to? (2018) · cites this paper as [4]
Citations
Cites
Broad, W. J. (1981) · Science · doi:10.1126/science.7209527 · Cited by 127
Participation of Community Hospitals in Clinical Trials
Begg, C. B., Carbone, P. P., Elson, P. J., & Zelen, M. (1982) · New England Journal of Medicine · doi:10.1056/nejm198205063061803 · Cited by 80
Koshland, D. E. (1987) · Science · doi:10.1126/science.3798097 · Cited by 74
Quality of Institutional Participation in Multicenter Clinical Trials
Sylvester, R. J., Pinedo, H. M., Pauw, M. D., Staquet, M. J., Buyse, M. E., Renard, J., Bonadonna, G., & The Active Participants in the EORTC Soft Tissue and Bone Sarcoma Cooperative Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198110083051503 · Cited by 71
Scientific Misconduct in Investigations Drug Trials
Shapiro, M. F., & Charrow, R. P. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503143121128 · Cited by 54
The Role of Data Audits in Detecting Scientific Misconduct
Shapiro, M. F. (1989) · JAMA · doi:10.1001/jama.1989.03420170049029 · Cited by 50
Rennie, D. (1989) · JAMA · doi:10.1001/jama.1989.03420170087035 · Cited by 38
Reassessment of patient response to monoclonal antibody 3F8.
Cheung, N. V., Lazarus, H. M., Miraldi, F. D., Berger, N. A., Abramowsky, C. R., Saarinen, U. M., Spitzer, T. R., Strandjord, S. E., & Coccia, P. F. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.671 · Cited by 33
Territorialism in Two Species of Salamanders
Grant, W. C. (1955) · Science · doi:10.1126/science.121.3135.137 · Cited by 31
The Harvard fraud case: where does the problem lie?
Knox, R. (1983) · JAMA · doi:10.1001/jama.1983.03330380003001 · Cited by 26
Cited by
Larson, R., Dodge, R., Burns, C., Lee, E., Stone, R., Schulman, P., Duggan, D., Davey, F., Sobol, R., & Frankel, Sr. (1995) · Blood · doi:10.1182/blood.v85.8.2025.bloodjournal8582025 · Cited by 626
Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P., Lee, E. J., Moore, J. O., Powell, B. L., & Schiffer, C. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322503 · Cited by 447
Is science really facing a reproducibility crisis, and do we need it to?
Fanelli, D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708272114 · Cited by 416
Baer, M. R., George, S. L., Dodge, R. K., O'Loughlin, K. L., Minderman, H., Caligiuri, M. A., Anastasi, J., Powell, B. L., Kolitz, J. E., Schiffer, C. A., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1224.h81602001224_1224_1232 · Cited by 366
Larson, R. A., Dodge, R. K., LINKER, C. A., Stone, R. M., Powell, B. L., Lee, E. J., Schulman, P., Davey, F. R., Frankel, S. R., Bloomfield, C. D., et al. (1998) · PubMed · doi:10.1182/blood.v92.5.1556 · Cited by 269
Metadata
- Authors
- Weiss, R. B.
- Affiliations
- Walter Reed National Military Medical Center (US)
- Corresponding author
- Weiss, Raymond B.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1993-07-28
- Volume
- 270
- Issue
- 4
- Pages
- 459
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2059673652
- Cited by
- 70
- References
- 14
- Citations by year
- 2025: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 6 · 2013: 2
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-41287, CA 16450, U10CA026806, CA 26806, U10CA016450, U10CA041287)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Keywords
- source documents, informed consent forms, tumor response assessment, protocol deviations, cancer clinical trials
- MeSH terms
- Clinical Trials as Topic, Data Collection, Humans, Medical Audit, Medical Records, National Institutes of Health (U.S.), Neoplasms, Retrospective Studies, United States, Scientific Misconduct
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Successful System of Scientific Data Audits for Clinical Trials: A Report From the Cancer and Leukemia Group B. https://app.cochat.ai/papers/10.1001/jama.1993.03510040063030
- The paper
- Weiss, R. B. (1993). A Successful System of Scientific Data Audits for Clinical Trials: A Report From the Cancer and Leukemia Group B. JAMA. https://doi.org/10.1001/jama.1993.03510040063030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.